Preferred Label : insulin, isophane;

MeSH definition : An intermediate-acting INSULIN preparation with onset time of 2 hours and duration of 24 hours. It is produced by crystallizing ZINC-insulin-PROTAMINES at neutral pH 7. Thus it is called neutral protamine Hagedorn for inventor Hans Christian Hagedorn.;

MeSH synonym : insulin, NPH; isophane insulin; protamine hagedorn insulin; hagedorn insulin, protamine; Neutral Protamine Hagedorn Insulin; isophane insulin, regular; regular isophane insulin; nph insulin;

CISMeF synonym : insulin, protamine hagedorn;

Related MeSH term : insulin, protamine zinc; Protamine Zinc Insulin; Zinc Insulin, Protamine;

MeSH CAS label : insulin isophane;

Registry Number MeSH : 53027-39-7;

Is substance : O;

Details


Main resources

You can consult :

An intermediate-acting INSULIN preparation with onset time of 2 hours and duration of 24 hours. It is produced by crystallizing ZINC-insulin-PROTAMINES at neutral pH 7. Thus it is called neutral protamine Hagedorn for inventor Hans Christian Hagedorn.

https://www.cochrane.org/fr/CD005613/ENDOC_analogues-de-linsuline-action-ultra-prolongee-compares-linsuline-nph-insuline-isophane-humaine-pour
2020
France
United Kingdom
review of literature
french abstract
Adult
Diabetes
adulthood
diabetes mellitus, nos
Isophane Insulin, Human
insulin, isophane
Adult
insulin analogs
isophane insulin
homo sapiens
adult
long-acting insulin, nos
diabetes mellitus
insulin, isophane

---
https://www.has-sante.fr/portail/jcms/c_2770190/fr/umuline
https://www.has-sante.fr/portail/jcms/c_1363131/umuline
https://www.has-sante.fr/portail/jcms/c_560696/fr/umuline-nph-pen
2017
false
France
French
Isophane Insulin, Human
insulin, isophane
diabetes mellitus
hypoglycemic agents
pregnancy
insulin (human)
insulin, regular, human
recombinant proteins
biphasic insulins
insulin, Short-Acting
insulin (human)
insulin (human)
evaluation of the transparency committee

---
http://www.has-sante.fr/portail/jcms/c_2608676/fr/actrapid-insulatard-mixtard
http://www.has-sante.fr/portail/jcms/c_1278879/actrapid-mixtard-insulatard
2016
false
France
French
Isophane Insulin, Human
evaluation of the transparency committee
biphasic insulins
insulin, isophane
insulin (human)
insulin (human)
treatment outcome
hypoglycemic agents
insurance, health, reimbursement
injections, subcutaneous
diabetes mellitus
insulin, Short-Acting
recombinant proteins
insulin, regular, human
insulin (human)

---
https://www.ema.europa.eu/medicines/human/EPAR/insulin-human-winthrop
2012
false
United Kingdom
English
French
syndication feed
hypoglycemic agents
diabetes mellitus
hyperglycemic hyperosmolar nonketotic coma
diabetic ketoacidosis
insulin
insulin, long-acting
hypoglycemic agents
insulin, long-acting
drug interactions
pregnancy
breast feeding
insulin, isophane
insulin, isophane
treatment outcome
drug evaluation
drug approval
drug labeling
insulin (human)
insulin, regular, human
insulin (human)
insulin (human)
insulin, Short-Acting
insulin, Short-Acting
biphasic insulins
biphasic insulins
insulin, regular, human
package leaflet
drug evaluation
summary of product characteristics

---
https://www.ema.europa.eu/medicines/human/EPAR/Protaphane
2012
United Kingdom
French
English
syndication feed
hypoglycemic agents
insulin, isophane
diabetes mellitus
hypoglycemic agents
insulin, long-acting
treatment outcome
drug evaluation
hypoglycemic agents
insulin, isophane
insulin, isophane
insulin (human)
insulin, regular, human
insulin, regular, human
recombinant proteins
drug evaluation
summary of product characteristics
package leaflet

---
https://www.ema.europa.eu/medicines/human/EPAR/NovoMix
2008
United Kingdom
French
English
syndication feed
insulin aspart
insulin aspart
biphasic insulins
biphasic insulins
hypoglycemic agents
diabetes mellitus
hypoglycemic agents
treatment outcome
drug evaluation
protamines
drug combinations
insulin aspart
insulin, isophane
insulin, isophane
injections, subcutaneous
insulin aspart, insulin aspart protamine drug combination 30:70
insulin aspart, insulin aspart protamine drug combination 30:70
package leaflet
drug evaluation
summary of product characteristics

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=66754862
2008
France
French
recombinant proteins
insulin lispro
protamines
insulin lispro
biphasic insulins
neutral protamine lispro insulin
insulin lispro, isophane insulin lispro drug combination (25:75)
insulin, isophane
injections
drug information

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=69304169
2008
France
French
recombinant proteins
injections, subcutaneous
insulin lispro
protamines
insulin lispro
biphasic insulins
neutral protamine lispro insulin
insulin lispro, isophane insulin lispro drug combination (25:75)
insulin, isophane
drug information

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=61842753
2008
France
French
insulin lispro
insulin, isophane
injections, subcutaneous
recombinant proteins
insulin lispro
protamines
biphasic insulins
neutral protamine lispro insulin
isophane insulin, insulin lispro drug combination 50:50
drug information

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=61650831
2008
France
French
insulin lispro
injections, subcutaneous
suspensions
recombinant proteins
insulin lispro
protamines
isophane insulin, insulin lispro drug combination 50:50
biphasic insulins
neutral protamine lispro insulin
insulin, isophane
drug information

---
https://rmlg.uliege.be/article/1822
2008
Belgium
French
insulin aspart
biphasic insulins
insulin aspart
diabetes mellitus, type 2
hypoglycemic agents
injections, subcutaneous
belgium
insulin, isophane
journal article
drug information

---
https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_NovoMix30-Fr.pdf
2006
Canada
French
biphasic insulins
insulin aspart
protamines
drug combinations
canada
diabetes mellitus
hypoglycemic agents
insulin aspart
insulin, isophane
insulin aspart, insulin aspart protamine drug combination 30:70
drug evaluation

---
Nous contacter.
18/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.